Associations of upregulation of SIRT3 and SIRT4 with dasatinib sensitivity were consistent with previously reported protective roles of both genes in the treatment of hepatocellular carcinoma and with the positive effect of SIRT3 upregulation on HCC sensitivity to a variety of antitumor agents, including the kinase inhibitors sorafenib and regorafenib [32]. This evidence concerns the gene SIRT4 and hepatocellular carcinoma.